The short version of Visceral adiposity fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-11. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
=== Magnetic methods === Magnetic field directed self-assembly (MFDSA) allows the manipulation of dispersion and subsequent assembly of magnetic nanoparticles. This is widely used in the development of advanced materials whereby inorganic nanoparticles (NPs) are dispersed in polymers in order to enhance the properties of the materials. The magnetic field technique allows the assembling of particles in 3D by doing the assembly in a dilute suspension where the solvent does not evaporate. It also does not need to use a template, and the approach also improve the magnetic anisotropy along the chain direction.
==== Venus landings ==== In 1970, the Soviet Union's Venera 7 marked the first time a spacecraft was able to return data after landing on another planet. Venera 7 held a resistant thermometer and an aneroid barometer to measure the temperature and atmospheric pressure on the surface, the transmitted data showed 475 C at the surface, and a pressure of 92 bar. In 1975, Venera 9 established an orbit around Venus and successfully returned the first photography of the surface of Venus. Venera 10 landed on Venus and followed with further photography shortly after. NASA initiated the Pioneer Venus project in 1978, successfully deploying four small probes into the Venusian atmosphere on December 9, 1978. The probes confirmed that Venus has little if any magnetic field, and cameras detected lightning in the atmosphere. The last transmissions were received on October 8, 1992, as its decaying orbit no longer permitted communications. The spacecraft burned up the atmosphere soon after, ending a successful 14-year mission that was planned to last only eight months. In 1981, Venera 13 performed a successful soft-landing on Venus and marked the first probe to drill into the surface of another planet and take a sample. Venera 13 also took an audio sample of the Venusian environment, marking another first. Venera 13 returned the first color images of the surface of Venus, revealing an orange-brown flat bedrock surface covered with loose regolith and small flat thin angular rocks. Venera 14, an identical spacecraft to Venera 13, was launched 5 days apart with a similar mission profile.
== Allergies == Plantain and banana allergies occur with typical characteristics of food allergy or latex fruit syndrome, including itching and mild swelling of the lips, tongue, palate or throat, skin rash, stomach complaints or anaphylactic shock. Among more than 1000 proteins identified in Musa species were numerous previously described protein allergens.
Sources: en.wikipedia.org
At the February 1945 Yalta Conference, the Allies attempted to define the framework for a postwar settlement in Europe. The Allies could not reach firm agreements on the crucial questions: the occupation of Germany, postwar reparations from Germany, and the fate of Poland. No final consensus was reached on Germany, other than to agree to a Soviet request for reparations totaling $10 billion "as a basis for negotiations". Debates over the composition of Poland's postwar government were also acrimonious. The Yalta Conference ended with "a declaration on liberated Europe pledging respect for democratic forms and providing a diplomatic mechanism for constituting a generally acceptable Polish government". After Roosevelt's death on April 12, Harry S. Truman succeeded him as US president. Truman was unaware of Roosevelt's plans for post-war engagement with the Soviet Union, and more generally uninformed about foreign policy and military matters. The new president, therefore, was initially reliant on a set of advisers (including Ambassador to the Soviet Union Averell Harriman and Secretary of the Navy James Forrestal). This group tended to take a harder line towards Moscow than Roosevelt had done. Truman lacked the foreign policy confidence that pushed Roosevelt's initiatives with the Soviet Union. Eager to prove himself, Truman depended on his advisors, with Harriman using this lack of confidence to push his argument that Roosevelt's position on Stalin was based on fear, therefore Truman needed to prove the grit of the US. US-Soviet relations became decidedly colder.
The Western blots were first stained with Ponceau and then incubated with IgG antibodies against hGH and subsequently treated with α-mIgG HRP and α-hIgG 647 for visualisation. In the hIgG-hGH conjugate Western blot (nonreducing conditions), two separate bands with different molecular weights are visible after immunodetection. These can be contributed to the formation of mono- and bi-conjugated hGH to hIgG.
=== Biotransformation === Caffeate O-methyltransferase is an enzyme responsible for the transformation of caffeic acid into ferulic acid. Caffeic acid and related o-diphenols are rapidly oxidized by o-diphenol oxidases in tissue extracts.
Sources: en.wikipedia.org
== Medical uses == Protriptyline is used primarily to treat depression and to treat the combination of symptoms of anxiety and depression. Like most antidepressants of this chemical and pharmacological class, protriptyline has also been used in limited numbers of patients to treat panic disorder, obsessive-compulsive disorder, attention-deficit/hyperactivity disorder, enuresis, eating disorders such as bulimia nervosa, cocaine dependency, and the depressive phase of bipolar disorder (manic-depressive) disorder. It has also been used to support smoking cessation programs. Protriptyline is available as 5 mg and 10 mg tablets. Doses range from 15 to 40 mg per day and can be taken in one daily dose or divided into up to four doses daily. Some people with severe depression may require up to 60 mg per day. In adolescents and people over age 60, therapy should be initiated at a dose of 5 mg three times a day and increased under the supervision of a physician as needed. Patients over age 60 who are taking daily doses of 20 mg or more should be closely monitored for side effects such as rapid heart rate and urinary retention. Like all TCAs, protriptyline should be used cautiously and with close physician supervision. This is especially so for persons with glaucoma, especially angle-closure glaucoma (the most severe form) or urinary retention, for men with benign prostatic hyperplasia (enlarged prostate gland), and for the elderly.
== Naturally occurring nuclides that are not primordial == Some unstable isotopes which occur naturally (such as 14C, 3H, and 239Pu) are not primordial, as they must be constantly regenerated. This occurs by cosmic radiation (in the case of cosmogenic nuclides such as 14C and 3H), or (rarely) by such processes as geonuclear transmutation (neutron capture by uranium in the case of 237Np and 239Pu). Other examples of common naturally occurring but non-primordial nuclides are isotopes of radon, polonium, and radium, which are all radiogenic daughters of uranium decay and are found in uranium ores. The stable argon isotope 40Ar is actually more common as a radiogenic nuclide than as a primordial nuclide, forming almost 1% of the Earth's atmosphere, which is generated by the electron capture decay of the extremely long-lived radioactive primordial isotope 40K, whose half-life is on the order of a billion years and thus has been generating argon since early in the Earth's existence. (Primordial argon was dominated by the alpha process nuclide 36Ar, which is significantly rarer than 40Ar on Earth.) And the classical decay chains of radiogenic elements derive from the long-lived radioactive primordial nuclides 232Th, 235U, and 238U. These nuclides are described as geogenic, meaning that they are decay or fission products of uranium or other actinides in subsurface rocks. All such nuclides have shorter half-lives than their parent radioactive primordial nuclides.
Typically, for adults, 100 mg trelagliptin is given orally once a week. Similar drugs in the same class as trelagliptin are administered once daily while trelagliptin is administered once weekly. A dosing of once per week is advantageous as a reduction in the frequency of required dosing is known to increase patient compliance. A recent meta-analysis published by Dutta et al. highlighted the good glycaemic efficacy and safety of this molecule as compared to peer DPP4 inhibitors which have to be taken daily like alogliptin, sitagliptin, linagliptin, teneligliptin, anagliptin or vildagliptin, having an advantage of reducing the monthly pill count from 30 to 4.
Silent mutations, also called synonymous or samesense mutations, are mutations in DNA that do not have an observable effect on the organism's phenotype, as they produce the same amino acid though a single base pairing has been altered. The phrase silent mutation is often used interchangeably with the phrase synonymous mutation; however, synonymous mutations are not always silent, nor vice versa. Synonymous mutations can affect transcription, splicing, mRNA transport, and translation, any of which could alter phenotype, rendering the synonymous mutation non-silent. The substrate specificity of the tRNA to the rare codon can affect the timing of translation, and in turn the co-translational folding of the protein. This is reflected in the codon usage bias that is observed in many species. Mutations that cause the altered codon to produce an amino acid with similar functionality (e.g. a mutation producing leucine instead of isoleucine) are often classified as silent; if the properties of the amino acid are conserved, this mutation does not usually significantly affect protein function.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.